Emily Minkow serves as Executive at Prevail Therapeutics Inc., where they oversee executive responsibilities. Since joining the company, Emily Minkow has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 22, 2021 involved transacting 13,000 shares valued at $0.
Emily Minkow currently holds 13,000 shares of Prevail Therapeutics Inc. (PRVL), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Emily Minkow has been a net neutral trader of PRVL stock. They have purchased $0 and sold $0 worth of shares.
Emily Minkow's most recent insider trade was on Jan 22, 2021, when they sold 13,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $0.18 |
| Discretionary |